NeoStem: Safety board recommends continuing heart-drug trial

|By:, SA News Editor

NeoStem (NBS +2.2%) say that the Data Safety Monitoring Board for the Phase II trial of its AMR-001 drug has recommended continuing the study following a third interim data and safety review.

AMR-001 is being tested for its ability to preserve heart function after a severe heart attack, with the trial comprising 160 patients. (PR)